Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 178M | 7% |
| Gross Profit | 164M | 24.2% |
| Cost of Revenue | 14M | 59% |
| Operating expense | 198M | 8.4% |
| Net Income | -42M | 54.3% |
| EBITDA | -30M | 62.6% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 821M | 1.7% |
| Total Liabilities | 665M | 3.4% |
| Total Equity | 156M | 4.8% |
| Shares Outstanding | 126M | 0.5% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 4.4M | 108.3% |
| Cash from investing | -49,000 | 512.5% |
| Cash from financing | 6.6M | 2293.4% |
EPS
Financial Highlights for Apellis Pharmaceuticals in Q2 '25
Apellis Pharmaceuticals reported a revenue of 178M, which is a 7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 164M, marking a 24.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 14M, a -59% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 198M, showing a -8.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -42M, showing a 54.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -30M, showing a 62.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Apellis Pharmaceuticals with growth in revenue, gross profit, and net income.
